In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
Mercedes-Benz taps Modern Meadow for 80% plant-based leather
In Germany, luxury car manufacturer Mercedes-Benz has partnered with New Jersey biodesign firm Moden Meadow to develop a next-generation leather alternative for its CONCEPT...
Bioluminescent dress from van Herpen portends era of living couture
In France, Dutch fashion designer Iris van Herpen has unveiled a dress embedded with 125 million bioluminescent algae at Paris Haute Couture Week 2025....
Stella McCartney’s latest sneaker can be composted, smells of cinnamon
In London, sustainable fashion pioneer Stella McCartney has unveiled a new version of its S-Wave sneakers, featuring soles made entirely from BioCir Flex, a...